<n-docbody><doc bill="Y"><content.metadata.block><cmd.identifiers><cmd.cites><cmd.second.line.cite><bop/><bos/>Multidistrict Lit Man § 6:14<eos/><eop/></cmd.second.line.cite></cmd.cites></cmd.identifiers></content.metadata.block><prop.block><prop.head toc-guid=""><bop/><bos/><headtext>Multidistrict Litigation Manual</headtext><eos/><eop/></prop.head><content.metadata.block><cmd.dates><cmd.currency.default iso.d="20190501"><bop/><bos/>May 2019 Update<eos/><eop/></cmd.currency.default></cmd.dates></content.metadata.block><author.line><bop/><bos/><author>David F. Herr[<footnote.reference refid="If547f9716b3e11e99b03e53d6dd36aa2">a0</footnote.reference>]</author><eos/><eop/></author.line><prop.head toc-guid="I97b7f560933b11da99e2b07024dacc26"><bop/><bos/><label.name>Part</label.name><label.designator>I.</label.designator><headtext>Handling Cases Before the Judicial Panel on Multidistrict Litigation</headtext><eos/><eop/></prop.head><prop.head toc-guid="I1c3ad730933c11da99e2b07024dacc26"><bop/><bos/><label.name>Chapter</label.name><label.designator>6.</label.designator><headtext>Selection of a Transferee District</headtext><eos/><eop/></prop.head></prop.block><message.block><include.copyright n-include_collection="w_wlnv_msg" n-include_guid="I1DA35ED81DD211B281BAD200220BDFCA">Copyright (c) 2017 Thomson/RIA All rights reserved.</include.copyright></message.block><section><section.front><doc.title toc-guid="I94f3c38ae1e311da9c26e67ca3b71335"><head parent="doc.title"><bop/><bos/><label.name>§ </label.name><label.designator>6:14.</label.designator><headtext>Factors articulated by the Panel in selecting transferee district—Familiarity with issues</headtext><eos/><eop/></head></doc.title></section.front><section.body><para><bop/><bos/><paratext>The Panel has expressed its preference for transferring actions to the district in which the judge handling the pending actions has acquired the greatest familiarity with the nature of the cases and the issues.[<eos/><bos/><footnote.reference refid="If54820806b3e11e99b03e53d6dd36aa2">1</footnote.reference>] This factor may be based on the judge&apos;s experience in handling the civil actions filed in the potential transferee district[<footnote.reference refid="If54847906b3e11e99b03e53d6dd36aa2">2</footnote.reference>] or may be based on some other involvement or experience in the case. <eos/><bos/>For example, if the judge presided over grand jury proceedings or government criminal proceedings, that judge&apos;s availability may be a very logical factor both favoring transfer and favoring selection of that judge&apos;s district as the transferee district.[<eos/><bos/><footnote.reference refid="If5486ea06b3e11e99b03e53d6dd36aa2">3</footnote.reference>] Experience in related litigation, even if not strictly sharing common factual or legal issues, may be relevant to the Panel.[<eos/><bos/><footnote.reference refid="If5486ea16b3e11e99b03e53d6dd36aa2">4</footnote.reference>] Even experience gained in related, but now settled or dismissed cases, may be relevant.[<eos/><bos/><footnote.reference refid="If5486ea26b3e11e99b03e53d6dd36aa2">5</footnote.reference>] The Panel has considered the experience gained in handling similar actions involving unrelated parties but similar factual schemes and theories of recovery.[<eos/><bos/><footnote.reference refid="If548e3d06b3e11e99b03e53d6dd36aa2">6</footnote.reference>] Experience in handling similar MDL litigation involving a corporate predecessor was viewed in one matter as an important factor in selecting the transferee district.[<eos/><bos/><footnote.reference refid="If5490ae06b3e11e99b03e53d6dd36aa2">7</footnote.reference>] Even successful handing of other cases transferred under section 1407, without regard to the specific issues, may be important to the Panel.[<eos/><bos/><footnote.reference refid="If5490ae16b3e11e99b03e53d6dd36aa2">8</footnote.reference>] Indeed, the opportunity to transfer to a judge with prior experience as an MDL transferee judge is frequently mentioned in Panel transfer decisions as a reason for selecting a particular distict.[<eos/><bos/><footnote.reference refid="If5490ae26b3e11e99b03e53d6dd36aa2">9</footnote.reference>] As powerful as this factor may be, however, it is obviously limited by the Panel&apos;s efforts to spread MDLs around so particular judges are not unduly burdened by the cases, and to make the assignments more broadly available. <eos/><bos/>Thus, the Panel will on occasion identify the fact that a judge is experienced transferee judge without having a current MDL docket as a reason to transfer to that judge&apos;s district.[<eos/><bos/><footnote.reference refid="If54931f06b3e11e99b03e53d6dd36aa2">10</footnote.reference>] This is not a make-or-break factor, however. <eos/><bos/>The Panel also has expressed willingness to transfer to a judge who is experienced, but has not previously served as transferee judge.[<eos/><bos/><footnote.reference refid="If54931f16b3e11e99b03e53d6dd36aa2">11</footnote.reference>] The Panel has made it clear that transfer in this circumstance does not result in coordinated or consolidated pretrial proceedings between the two litigations.[<eos/><bos/><footnote.reference refid="If54931f26b3e11e99b03e53d6dd36aa2">12</footnote.reference>] This concern of the Panel in this regard is logical, given the opportunities for more efficient handling and coordination with actions that may still be pending.<eos/></paratext><eop/></para><para><bop/><bos/><paratext>This factor may be very important to the Panel. <eos/><bos/>The availability of a judge experienced with the litigation may overcome otherwise significant factors in selecting a transferee district. <eos/><bos/>For example, the Panel may transfer cases to a district where a judge has great familiarity with the litigation even if it is a district other than that where a related government action was handled[<footnote.reference refid="If54959006b3e11e99b03e53d6dd36aa2">13</footnote.reference>] or where reorganization proceedings are pending.[<eos/><bos/><footnote.reference refid="If54959026b3e11e99b03e53d6dd36aa2">14</footnote.reference>] The Panel has also transferred a docket to an adjacent district to one where prior MDL centralized proceedings against the same defendant were held.[<eos/><bos/><footnote.reference refid="If54980116b3e11e99b03e53d6dd36aa2">15</footnote.reference>] The opportunity to assign a matter to an experienced transferee judge is evidently powerful in some cases. <eos/><bos/>In one case, the Panel assigned the matter to a district because an experienced transferee judge available despite the fact no action was pending in that district.[<eos/><bos/><footnote.reference refid="If54980126b3e11e99b03e53d6dd36aa2">16</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>The experience of the potential transferee judge often correlates with another important factor—advancement of the cases toward trial. <eos/><bos/>If cases are being managed well, cases that have been pending longer are more likely to be progressing towards trial.[<eos/><bos/><footnote.reference refid="If54980136b3e11e99b03e53d6dd36aa2">17</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>Although this factor often is expressed as a result of a particular judge&apos;s experience with the issues, occasionally the Panel is really selecting a transferee district base on this factor, and then selecting a transferee judge. <eos/><bos/>This is often the case with the factor of the opportunity to coordinate the centralized cases with cases pending in state court.[<eos/><bos/><footnote.reference refid="If54980156b3e11e99b03e53d6dd36aa2">18</footnote.reference>] In one docket the court noted that it was choosing the Northern District of California because of the District&apos;s experience with patent technology litigation.[<eos/><bos/><footnote.reference refid="If549a7216b3e11e99b03e53d6dd36aa2">19</footnote.reference>] Similarly, the Panel has identified a district&apos;s participation in the Patent Pilot Program as a reason for selecting it as a transferee district.[<eos/><bos/><footnote.reference refid="If549a7226b3e11e99b03e53d6dd36aa2">20</footnote.reference>]</paratext><eos/><eop/></para></section.body></section><author.footnotes><footnote ID="If547f9716b3e11e99b03e53d6dd36aa2"><label.designator>a0</label.designator><footnote.body><para><bop/><bos/><paratext>Maslon Edelman Borman &amp; Brand, LLP, Minneapolis, Minnesota.<eos/></paratext><eop/></para></footnote.body></footnote></author.footnotes><footnote.block><footnote ID="If54820806b3e11e99b03e53d6dd36aa2"><label.designator>1</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914075" w-serial-number="2034643817" w-seq-number="00001" w-ref-type="RP" w-pub-number="0007903" ID="I6c082bd16b3e11e99779f698461214a6">In re: Pre-Filled Propane Tank Antitrust Litigation, 53 F. Supp. 3d 1383 (U.S.J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2034078511" w-seq-number="00002" w-ref-type="RP" w-pub-number="0007903" ID="I6c082bd36b3e11e99779f698461214a6">In re Auto Body Shop Antitrust Litigation, 37 F. Supp. 3d 1388 (U.S.J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030316645" w-seq-number="00003" w-ref-type="RP" w-pub-number="0004637" ID="I6c082bd56b3e11e99779f698461214a6">In re Automated Transactions LLC Patent Litigation, 938 F. Supp. 2d 1353 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029837285" w-seq-number="00004" w-ref-type="RP" w-pub-number="0004637" ID="I6c082bd76b3e11e99779f698461214a6">In re Hyundai and Kia Fuel Economy Litigation, 923 F. Supp. 2d 1364 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029450282" w-seq-number="00005" w-ref-type="RP" w-pub-number="0004637" ID="I6c082bd96b3e11e99779f698461214a6">In re Blue Cross Blue Shield Antitrust Litigation, 908 F. Supp. 2d 1373 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2027911974" w-seq-number="00006" w-ref-type="RP" w-pub-number="0004637" ID="I6c082bdb6b3e11e99779f698461214a6">In re Hardieplank Fiber Cement Siding Litigation, 867 F. Supp. 2d 1343 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2027084499" w-seq-number="00007" w-ref-type="RP" w-pub-number="0004637" ID="I6c082bdd6b3e11e99779f698461214a6">In re American Medical Systems, Inc., Pelvic Repair System Products Liability Litigation, 844 F. Supp. 2d 1359 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2025911124" w-seq-number="00008" w-ref-type="RP" w-pub-number="0004637" ID="I6c082bdf6b3e11e99779f698461214a6">In re Bank of America Credit Protection Marketing and Sales Practices Litigation, 804 F. Supp. 2d 1372 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2015254467" w-seq-number="00009" w-ref-type="RP" w-pub-number="0004637" ID="I6c082be16b3e11e99779f698461214a6">In re Michelin North America, Inc., PAX System Marketing and Sales Practices Litigation, 536 F. Supp. 2d 1365 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2007602296" w-seq-number="00010" w-ref-type="RP" w-pub-number="0004637" ID="I6c082be36b3e11e99779f698461214a6">In re American Investors Life Ins. Co. Annuity Marketing and Sales Practices Litigation, 398 F. Supp. 2d 1361 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2003212309" w-seq-number="00011" w-ref-type="RP" w-pub-number="0004637" ID="I6c082be56b3e11e99779f698461214a6">In re Cardiac Devices Qui Tam Litigation, 254 F. Supp. 2d 1370 (J.P.M.L. 2003)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2003212312" w-seq-number="00012" w-ref-type="RP" w-pub-number="0004637" ID="I6c082be76b3e11e99779f698461214a6">In re Medco Health Solutions, Inc., 254 F. Supp. 2d 1364 (J.P.M.L. 2003)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2002691943" w-seq-number="00013" w-ref-type="RP" w-pub-number="0004637" ID="I6c082be96b3e11e99779f698461214a6">In re Commercial Money Center, Inc., Equipment Lease Litigation, 229 F. Supp. 2d 1379 (J.P.M.L. 2002)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2002528277" w-seq-number="00014" w-ref-type="RP" w-pub-number="0004637" ID="I6c082beb6b3e11e99779f698461214a6">In re Neurontin Antitrust Litigation, 217 F. Supp. 2d 1380 (J.P.M.L. 2002)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1979116134" w-seq-number="00015" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="859" ID="I6c082bed6b3e11e99779f698461214a6">In re Data General Corp. Antitrust Litigation, 470 F. Supp. 855, 859 (J.P.M.L. 1979)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1979102645" w-seq-number="00016" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1298" ID="I6c082bef6b3e11e99779f698461214a6">In re Cutter Laboratories, Inc. “Braunwald-Cutter” Aortic Heart Valve Products Liability Litigation, 465 F. Supp. 1295, 1298 (J.P.M.L. 1979)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1978103945" w-seq-number="00017" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1350" ID="I6c082bf16b3e11e99779f698461214a6">In re Wiring Device Antitrust Litigation, 444 F. Supp. 1348, 1350 (J.P.M.L. 1978)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1977126582" w-seq-number="00018" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="270" ID="I6c082bf36b3e11e99779f698461214a6">In re New York City Municipal Securities Litigation, 439 F. Supp. 267, 270 (J.P.M.L. 1977)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1977126500" w-seq-number="00019" w-ref-type="RP" w-pub-number="0000345" ID="I6c082bf56b3e11e99779f698461214a6">In re Hawaiian Hotel Room Rate Antitrust Litigation, 438 F. Supp. 935 (J.P.M.L. 1977)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1977125581" w-seq-number="00020" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1130" ID="I6c082bf76b3e11e99779f698461214a6">In re South Cent. States Bakery Products Antitrust Litigation, 433 F. Supp. 1127, 1130 (J.P.M.L. 1977)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1976127840" w-seq-number="00021" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1165" ID="I6c082bf96b3e11e99779f698461214a6">In re FMC Corp. Patent Litigation, 422 F. Supp. 1163, 1165 (J.P.M.L. 1976)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1975108425" w-seq-number="00022" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="319" ID="I6c082bfb6b3e11e99779f698461214a6">In re Westinghouse Elec. Corp. Uranium Contracts Litigation, 405 F. Supp. 316, 319 (J.P.M.L. 1975)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1975108420" w-seq-number="00023" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="310" ID="I6c082bfd6b3e11e99779f698461214a6">In re Ryder Truck Lines, Inc. Employment Practices Litigation, 405 F. Supp. 308, 310 (J.P.M.L. 1975)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1975106943" w-seq-number="00024" w-ref-type="RP" w-pub-number="0000345" ID="I6c082bff6b3e11e99779f698461214a6">In re Air Crash Disaster Near Papeete, Tahiti, on July 22, 1973, 397 F. Supp. 886 (J.P.M.L. 1975)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1975105860" w-seq-number="00025" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1056" ID="I6c082c016b3e11e99779f698461214a6">In re L. E. Lay &amp; Co. Antitrust Litigation, 391 F. Supp. 1054, 1056 (J.P.M.L. 1975)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1974106650" w-seq-number="00026" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="991" ID="I6c082c036b3e11e99779f698461214a6">In re Midwest Milk Monopolization Litigation, 379 F. Supp. 989, 991 (J.P.M.L. 1974)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1973105262" w-seq-number="00027" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1287" ID="I6c082c056b3e11e99779f698461214a6">In re Air Crash Disaster Near Pellston, Michigan, on May 9, 1970, 357 F. Supp. 1286, 1287 (J.P.M.L. 1973)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1971105972" w-seq-number="00028" w-ref-type="RP" w-pub-number="0000345" ID="I6c082c076b3e11e99779f698461214a6">In re CBS Color Tube Patent Litigation, 329 F. Supp. 540 (J.P.M.L. 1971)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1971104460" w-seq-number="00029" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1018" ID="I6c082c096b3e11e99779f698461214a6">In re Carrom Trademark Litigation, 322 F. Supp. 1016, 1018 (J.P.M.L. 1971)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1969100256" w-seq-number="00030" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1403" ID="I6c082c0b6b3e11e99779f698461214a6">In re Antibiotic Drugs, 295 F. Supp. 1402, 1403 (J.P.M.L. 1968)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54847906b3e11e99b03e53d6dd36aa2"><label.designator>2</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914075" w-serial-number="2029837285" w-seq-number="00031" w-ref-type="RP" w-pub-number="0004637" ID="I6c0a4eb16b3e11e99779f698461214a6">In re Hyundai and Kia Fuel Economy Litigation, 923 F. Supp. 2d 1364 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029450282" w-seq-number="00032" w-ref-type="RP" w-pub-number="0004637" ID="I6c0a4eb36b3e11e99779f698461214a6">In re Blue Cross Blue Shield Antitrust Litigation, 908 F. Supp. 2d 1373 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2025911124" w-seq-number="00033" w-ref-type="RP" w-pub-number="0004637" ID="I6c0a4eb56b3e11e99779f698461214a6">In re Bank of America Credit Protection Marketing and Sales Practices Litigation, 804 F. Supp. 2d 1372 (J.P.M.L. 2011)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2015776119" w-seq-number="00034" w-ref-type="RP" w-pub-number="0004637" ID="I6c0a4eb76b3e11e99779f698461214a6">In re Air Crash Near Medan, Indonesia, On September 5, 2005, 544 F. Supp. 2d 1379 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2009440525" w-seq-number="00035" w-ref-type="RP" w-pub-number="0004637" ID="I6c0a4eb96b3e11e99779f698461214a6">In re Ocean Financial Corp. Prescreening Litigation, 435 F. Supp. 2d 1350 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2008986108" w-seq-number="00036" w-ref-type="RP" w-pub-number="0004637" ID="I6c0a4ebb6b3e11e99779f698461214a6">In re Marsh &amp; McLennan Companies, Inc., Securities Litigation, 429 F. Supp. 2d 1376 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2005839751" w-seq-number="00037" w-ref-type="RP" w-pub-number="0004637" ID="I6c0a4ebd6b3e11e99779f698461214a6">In re Testmasters Trademark Litigation, 350 F. Supp. 2d 1360 (J.P.M.L. 2004)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2003212312" w-seq-number="00038" w-ref-type="RP" w-pub-number="0004637" ID="I6c0a4ebf6b3e11e99779f698461214a6">In re Medco Health Solutions, Inc., 254 F. Supp. 2d 1364 (J.P.M.L. 2003)</cite.query> (judge presiding over cases in transferee district considering comprehensive settlement agreement); <cite.query w-src-number="0304914075" w-serial-number="1979116134" w-seq-number="00039" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="859" ID="I6c0a4ec16b3e11e99779f698461214a6">In re Data General Corp. Antitrust Litigation, 470 F. Supp. 855, 859 (J.P.M.L. 1979)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1977126582" w-seq-number="00040" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="270" ID="I6c0a4ec36b3e11e99779f698461214a6">In re New York City Municipal Securities Litigation, 439 F. Supp. 267, 270 (J.P.M.L. 1977)</cite.query> (factor “weighs significantly” in decision); <cite.query w-src-number="0304914075" w-serial-number="1976127840" w-seq-number="00041" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1165" ID="I6c0a4ec56b3e11e99779f698461214a6">In re FMC Corp. Patent Litigation, 422 F. Supp. 1163, 1165 (J.P.M.L. 1976)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1976126386" w-seq-number="00042" w-ref-type="RP" w-pub-number="0000345" ID="I6c0a4ec76b3e11e99779f698461214a6">In re Transocean Tender Offer Securities Litigation, 415 F. Supp. 382 (J.P.M.L. 1976)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1975105292" w-seq-number="00043" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="569" ID="I6c0a4ec96b3e11e99779f698461214a6">In re Stirling Homex Corp. Securities Litigation, 388 F. Supp. 567, 569–70 (J.P.M.L. 1975)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1973105262" w-seq-number="00044" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1287" ID="I6c0a4ecb6b3e11e99779f698461214a6">In re Air Crash Disaster Near Pellston, Michigan, on May 9, 1970, 357 F. Supp. 1286, 1287 (J.P.M.L. 1973)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If5486ea06b3e11e99b03e53d6dd36aa2"><label.designator>3</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914075" w-serial-number="2008986103" w-seq-number="00045" w-ref-type="RP" w-pub-number="0004637" ID="I6c0bae416b3e11e99779f698461214a6">In re Bayou Hedge Funds Investment Litigation, 429 F. Supp. 2d 1374 (J.P.M.L. 2006)</cite.query> (judge presided over 3 government civil actions and 2 criminal prosecutions); <cite.query w-src-number="0304914075" w-serial-number="1977126500" w-seq-number="00046" w-ref-type="RP" w-pub-number="0000345" ID="I6c0bae436b3e11e99779f698461214a6">In re Hawaiian Hotel Room Rate Antitrust Litigation, 438 F. Supp. 935 (J.P.M.L. 1977)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1977125581" w-seq-number="00047" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1130" ID="I6c0bae456b3e11e99779f698461214a6">In re South Cent. States Bakery Products Antitrust Litigation, 433 F. Supp. 1127, 1130 (J.P.M.L. 1977)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1974105351" w-seq-number="00048" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1399" ID="I6c0bae476b3e11e99779f698461214a6">In re Sta-Power Industries Securities and Antitrust Litigation, 372 F. Supp. 1398, 1399 (J.P.M.L. 1974)</cite.query> (SEC proceedings).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If5486ea16b3e11e99b03e53d6dd36aa2"><label.designator>4</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914075" w-serial-number="2043332699" w-seq-number="00049" w-ref-type="RP" w-pub-number="0007903" ID="I6c0c98a16b3e11e99779f698461214a6">In re National Prescription Opiate Litigation, 290 F. Supp. 3d 1375 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2043739968" w-seq-number="00050" w-ref-type="RP" w-pub-number="0007903" ID="I6c0c98a36b3e11e99779f698461214a6">In re Sorin 3T Heater-Cooler System Products Liability Litigation (No. II), 289 F. Supp. 3d 1335 (U.S.J.P.M.L. 2018)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2041792542" w-seq-number="00051" w-ref-type="RP" w-pub-number="0007903" ID="I6c0c98a56b3e11e99779f698461214a6">In re Brazilian Prosthetic Device Bribery Litigation, 283 F. Supp. 3d 1381 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2031270172" w-seq-number="00052" w-ref-type="RP" w-pub-number="0000999" ID="I6c0c98a76b3e11e99779f698461214a6">In re Effexor (Venlafaxine Hydrochloride) Products Liability Litigation, 2013 WL 4048494 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030316645" w-seq-number="00053" w-ref-type="RP" w-pub-number="0004637" ID="I6c0c98a96b3e11e99779f698461214a6">In re Automated Transactions LLC Patent Litigation, 938 F. Supp. 2d 1353 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2004373861" w-seq-number="00054" w-ref-type="RP" w-pub-number="0004637" ID="I6c0c98ab6b3e11e99779f698461214a6">In re Oxycontin Antitrust Litigation, 314 F. Supp. 2d 1388 (J.P.M.L. 2004)</cite.query> (transferee court familiarity with actions pending in that court and with patent at issue in litigation); <cite.query w-src-number="0304914075" w-serial-number="2004322194" w-seq-number="00055" w-ref-type="RP" w-pub-number="0004637" ID="I6c0c98ad6b3e11e99779f698461214a6">In re Laughlin Products, Inc., Patent Litigation, 313 F. Supp. 2d 1380 (J.P.M.L. 2004)</cite.query> (transfer to same district as related MDL litigation involving same patent).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If5486ea26b3e11e99b03e53d6dd36aa2"><label.designator>5</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914075" w-serial-number="2011109434" w-seq-number="00056" w-ref-type="RP" w-pub-number="0004637" ID="I6c0e6d616b3e11e99779f698461214a6">In re Morgan Stanley &amp; Co., Inc., Overtime Pay Litigation (No. II), 471 F. Supp. 2d 1353 (J.P.M.L. 2006)</cite.query> (earlier action had been settled, judge familiar with the issues would enhance prosepects for settlement); <cite.query w-src-number="0304914075" w-serial-number="2007565831" w-seq-number="00057" w-ref-type="RP" w-pub-number="0004637" ID="I6c0e6d636b3e11e99779f698461214a6">In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation, 398 F. Supp. 2d 1356 (J.P.M.L. 2005)</cite.query> (judge handled related MDL litigation involving similar issues; MDL–1575, <cite.query w-src-number="0304914075" w-serial-number="2007565831" w-seq-number="00058" w-ref-type="RS" w-pub-number="0004637" ID="I6c0e6d656b3e11e99779f698461214a6">In re Visa/Mastercard Antitrust Litigation);</cite.query> <cite.query w-src-number="0304914075" w-serial-number="2006294262" w-seq-number="00059" w-ref-type="RP" w-pub-number="0004637" ID="I6c0e6d676b3e11e99779f698461214a6"><ital>In re Acacia Media Technologies Corp. Patent Litigation</ital>, 360 F. Supp. 2d 1377 (J.P.M.L. 2005)</cite.query> (transfer to district where prior MDL actions relating to first round of complex patent dispute where tried and resolved); <cite.query w-src-number="0304914075" w-serial-number="2005443058" w-seq-number="00060" w-ref-type="RP" w-pub-number="0004637" ID="I6c0e6d696b3e11e99779f698461214a6">In re Neurontin Marketing and Sales Practices Litigation, 342 F. Supp. 2d 1350 (J.P.M.L. 2004)</cite.query> (experience over 8 years handling now-settled qui tam cases involving similar issues); <cite.query w-src-number="0304914075" w-serial-number="2005396824" w-seq-number="00061" w-ref-type="RP" w-pub-number="0004637" ID="I6c0e6d6b6b3e11e99779f698461214a6">In re Global Crossing Ltd. Securities Litigation, 341 F. Supp. 2d 1357 (J.P.M.L. 2004)</cite.query> (experience of transferee judge handling MDL litigation involving corporate predecessor of common defendant); <cite.query w-src-number="0304914075" w-serial-number="1975107931" w-seq-number="00062" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1403" ID="I6c0e6d6d6b3e11e99779f698461214a6">In re Panty Hose Seaming Patent Litigation, 402 F. Supp. 1401, 1403 (J.P.M.L. 1975)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If548e3d06b3e11e99b03e53d6dd36aa2"><label.designator>6</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914075" w-serial-number="2016316621" w-seq-number="00063" w-ref-type="RP" w-pub-number="0004637" ID="I6c1069316b3e11e99779f698461214a6">In re Flat Glass Antitrust Litigation (No. II), 559 F. Supp. 2d 1407 (J.P.M.L. 2008)</cite.query> (familiarity from handling earlier MDL docket involving different antitrust conspiracy, period, and type of price-fixing); <cite.query w-src-number="0304914075" w-serial-number="2005507528" w-seq-number="00064" w-ref-type="RP" w-pub-number="0004637" ID="I6c1069336b3e11e99779f698461214a6">In re Dollar General Corp. Fair Labor Standards Act Litigation, 346 F. Supp. 2d 1368 (J.P.M.L. 2004)</cite.query> (Fair Labor Standards Act cases transferred to court because of familiarity with opt-in collective action under FLSA); <cite.query w-src-number="0304914075" w-serial-number="1978104662" w-seq-number="00065" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="603" ID="I6c1069356b3e11e99779f698461214a6">In re Amoxicillin Patent and Antitrust Litigation, 449 F. Supp. 601, 603 (J.P.M.L. 1978)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="1974105351" w-seq-number="00066" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1399" ID="I6c1069376b3e11e99779f698461214a6">In re Sta-Power Industries Securities and Antitrust Litigation, 372 F. Supp. 1398, 1399 (J.P.M.L. 1974)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If5490ae06b3e11e99b03e53d6dd36aa2"><label.designator>7</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914075" w-serial-number="2005396824" w-seq-number="00067" w-ref-type="RP" w-pub-number="0004637" ID="I6c10de616b3e11e99779f698461214a6">In re Global Crossing Ltd. Securities Litigation, 341 F. Supp. 2d 1357 (J.P.M.L. 2004)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If5490ae16b3e11e99b03e53d6dd36aa2"><label.designator>8</label.designator><footnote.body><para><bop/><bos/><paratext>See, e.g., <cite.query w-src-number="0304914075" w-serial-number="2042803478" w-seq-number="00068" w-ref-type="RP" w-pub-number="0007903" ID="I6c117aa16b3e11e99779f698461214a6">In re CenturyLink Residential Customer Billing Disputes Litigation, 280 F. Supp. 3d 1383 (U.S.J.P.M.L. 2017)</cite.query> (noting Judge Michael Davis&apos;s skillful handling of other MDLs); <cite.query w-src-number="0304914075" w-serial-number="2005839846" w-seq-number="00069" w-ref-type="RP" w-pub-number="0004637" ID="I6c117aa36b3e11e99779f698461214a6">In re Educational Testing Service PLT 7-12 Test Scoring Litigation, 350 F. Supp. 2d 1363 (J.P.M.L. 2004)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If5490ae26b3e11e99b03e53d6dd36aa2"><label.designator>9</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914075" w-serial-number="2044758904" w-seq-number="00070" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f616b3e11e99779f698461214a6">In re Facebook, Inc., Consumer Privacy User Profile Litigation, 325 F. Supp. 3d 1362 (U.S.J.P.M.L. 2018)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2044246476" w-seq-number="00071" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f636b3e11e99779f698461214a6">In re Liquid Toppings Dispensing System (‘447) Patent Litigation, 291 F. Supp. 3d 1378 (U.S.J.P.M.L. 2018)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2044244569" w-seq-number="00072" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f656b3e11e99779f698461214a6">In re Apple Inc. Device Performance Litigation, 291 F. Supp. 3d 1371 (U.S.J.P.M.L. 2018)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2043740151" w-seq-number="00073" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f676b3e11e99779f698461214a6">In re Dealer Management Systems Antitrust Litigation, 291 F. Supp. 3d 1367 (U.S.J.P.M.L. 2018)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2043740563" w-seq-number="00074" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f696b3e11e99779f698461214a6">In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, 289 F. Supp. 3d 1332 (U.S.J.P.M.L. 2018)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2043332735" w-seq-number="00075" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f6b6b3e11e99779f698461214a6">In re Sonic Corp. Customer Data Security Breach Litigation, 276 F. Supp. 3d 1382 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2040902193" w-seq-number="00076" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f6d6b3e11e99779f698461214a6">In re Eliquis (Apixaban) Products Liability Litigation, 282 F. Supp. 3d 1354 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2042803478" w-seq-number="00077" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f6f6b3e11e99779f698461214a6">In re CenturyLink Residential Customer Billing Disputes Litigation, 280 F. Supp. 3d 1383 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2041398582" w-seq-number="00078" w-ref-type="RP" w-pub-number="0007903" ID="I6c134f716b3e11e99779f698461214a6">In re Qualcomm Antitrust Litigation, 273 F. Supp. 3d 1373 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2031762007" w-seq-number="00079" w-ref-type="RP" w-pub-number="0000999" ID="I6c134f736b3e11e99779f698461214a6">In re H &amp; R Block IRS Form 8863 Litigation, 2013 WL 5596032 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2031590397" w-seq-number="00080" w-ref-type="RP" w-pub-number="0000999" ID="I6c134f776b3e11e99779f698461214a6">In re Niaspan Antitrust Litigation, 2013 WL 5239728 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2031312873" w-seq-number="00081" w-ref-type="RP" w-pub-number="0000999" ID="I6c134f796b3e11e99779f698461214a6">In re Mykey Technology Inc. Patent Litigation, 2013 WL 4431251 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2031270136" w-seq-number="00082" w-ref-type="RP" w-pub-number="0000999" ID="I6c134f7b6b3e11e99779f698461214a6">In re Stericycle, Inc., Sterisafe Contract Litigation, 2013 WL 4048296 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030719349" w-seq-number="00083" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f7d6b3e11e99779f698461214a6">In re Stryker Rejuvenate, ABG II Hip Implant Products Liability Litigation, 949 F. Supp. 2d 1378 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030714943" w-seq-number="00084" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f7f6b3e11e99779f698461214a6">In re Nickelodeon Consumer Privacy Litigation, 949 F. Supp. 2d 1377 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030715068" w-seq-number="00085" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f816b3e11e99779f698461214a6">In re HSBC Bank USA, N.A., Debit Card Overdraft Fee Litigation, 949 F. Supp. 2d 1358 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030347236" w-seq-number="00086" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f836b3e11e99779f698461214a6">In re Mirena IUD Products Liability Litigation, 938 F. Supp. 2d 1355 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030364724" w-seq-number="00087" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f856b3e11e99779f698461214a6">In re Domestic Drywall Antitrust Litigation, 939 F. Supp. 2d 1371 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029887144" w-seq-number="00088" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f876b3e11e99779f698461214a6">In re New England Compounding Pharmacy, Inc., Products Liability Litigation, 924 F. Supp. 2d 1380 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029836955" w-seq-number="00089" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f896b3e11e99779f698461214a6">In re TRS Recovery Services, Inc., and TeleCheck Services, Inc., Fair Debt Collection Practices Act (FDCPA) Litigation, 923 F. Supp. 2d 1372 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029450282" w-seq-number="00090" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f8b6b3e11e99779f698461214a6">In re Blue Cross Blue Shield Antitrust Litigation, 908 F. Supp. 2d 1373 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029450564" w-seq-number="00091" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f8d6b3e11e99779f698461214a6">In re L&apos;oreal Wrinkle Cream Marketing and Sales Practices Litigation, 908 F. Supp. 2d 1381 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029450475" w-seq-number="00092" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f8f6b3e11e99779f698461214a6">In re On-Line Travel Co. (OTC)/Hotel Booking Antitrust Litigation, 908 F. Supp. 2d 1369 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029361080" w-seq-number="00093" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f916b3e11e99779f698461214a6">In re Nexium (Esomeprazole) Products Liability Litigation, 908 F. Supp. 2d 1362 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2028783991" w-seq-number="00094" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f936b3e11e99779f698461214a6">In re Biomet M2a Magnum Hip Implant Products Liability Litigation, 896 F. Supp. 2d 1339 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2028741449" w-seq-number="00095" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f956b3e11e99779f698461214a6">In re Air Crash at Georgetown, Guyana, On July 30, 2011, 895 F. Supp. 2d 1355 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2028469742" w-seq-number="00096" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f976b3e11e99779f698461214a6">In re Park West Galleries, Inc., Litigation, 887 F. Supp. 2d 1385 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2028431710" w-seq-number="00097" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f996b3e11e99779f698461214a6">In re Emerson Elec. Co. Wet/Dry Vac Marketing and Sale Practices Litigation, 885 F. Supp. 2d 1383 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2028387055" w-seq-number="00098" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f9b6b3e11e99779f698461214a6">In re Pradaxa (dabigatran etexilate) Products Liability Litigation, 883 F. Supp. 2d 1355 (J.P.M.L. 2012)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2028387049" w-seq-number="00099" w-ref-type="RP" w-pub-number="0004637" ID="I6c134f9d6b3e11e99779f698461214a6">In re Watson Fentanyl Patch Products Liability Litigation, 883 F. Supp. 2d 1350 (J.P.M.L. 2012)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54931f06b3e11e99b03e53d6dd36aa2"><label.designator>10</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914075" w-serial-number="2033539090" w-seq-number="00100" w-ref-type="RP" w-pub-number="0007903" ID="I6c1572416b3e11e99779f698461214a6">In re: Yosemite Nat. Park Hantavirus Litigation, 24 F. Supp. 3d 1370 (U.S.J.P.M.L. 2014)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2031813066" w-seq-number="00101" w-ref-type="RP" w-pub-number="0004637" ID="I6c1572436b3e11e99779f698461214a6">In re: Vehicle Carrier Services Antitrust Litigation, 978 F. Supp. 2d 1382 (U.S.J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030364823" w-seq-number="00102" w-ref-type="RP" w-pub-number="0004637" ID="I6c1572456b3e11e99779f698461214a6">In re E.I. du Pont de Nemours and Co. C-8 Personal Injury Litigation, 939 F. Supp. 2d 1374 (U.S.J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030284012" w-seq-number="00103" w-ref-type="RP" w-pub-number="0004637" ID="I6c1572476b3e11e99779f698461214a6">In re: Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation, 935 F. Supp. 2d 1362 (U.S.J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030714940" w-seq-number="00104" w-ref-type="RP" w-pub-number="0004637" ID="I6c1572496b3e11e99779f698461214a6">In re Subway Footlong Sandwich Marketing and Sales Practices Litigation, 949 F. Supp. 2d 1369 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030316404" w-seq-number="00105" w-ref-type="RP" w-pub-number="0004637" ID="I6c15724b6b3e11e99779f698461214a6">In re Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, 936 F. Supp. 2d 1379 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029877331" w-seq-number="00106" w-ref-type="RP" w-pub-number="0004637" ID="I6c15724d6b3e11e99779f698461214a6">In re Plavix Marketing, Sales Practices and Products Liability Litigation (No. II), 923 F. Supp. 2d 1376 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2029361076" w-seq-number="00107" w-ref-type="RP" w-pub-number="0004637" ID="I6c15724f6b3e11e99779f698461214a6">In re Nexium (Esomeprazole) Antitrust Litigation, 908 F. Supp. 2d 1360 (J.P.M.L. 2012)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54931f16b3e11e99b03e53d6dd36aa2"><label.designator>11</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914075" w-serial-number="2043739968" w-seq-number="00108" w-ref-type="RP" w-pub-number="0007903" ID="I6c1683b16b3e11e99779f698461214a6">In re Sorin 3T Heater-Cooler System Products Liability Litigation (No. II), 289 F. Supp. 3d 1335 (U.S.J.P.M.L. 2018)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2041398581" w-seq-number="00109" w-ref-type="RP" w-pub-number="0007903" ID="I6c1683b36b3e11e99779f698461214a6">In re Farxiga (Dapagliflozin) Products Liability Litigation, 273 F. Supp. 3d 1380 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2041792543" w-seq-number="00110" w-ref-type="RP" w-pub-number="0007903" ID="I6c1683b56b3e11e99779f698461214a6">In re FieldTurf Artificial Turf Marketing and Sales Practices Litigation, 254 F. Supp. 3d 1379 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2041399152" w-seq-number="00111" w-ref-type="RP" w-pub-number="0007903" ID="I6c1683b76b3e11e99779f698461214a6">In re Stryker Orthopaedics LFIT V40 Femoral Head Products Liability Litigation, 249 F. Supp. 3d 1353 (U.S.J.P.M.L. 2017)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2031720220" w-seq-number="00112" w-ref-type="RP" w-pub-number="0000999" ID="I6c1683b96b3e11e99779f698461214a6">In re Loestrin 24 Fe Antitrust Litigation, 2013 WL 5505369 (J.P.M.L. 2013)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2030714950" w-seq-number="00113" w-ref-type="RP" w-pub-number="0004637" ID="I6c1683bb6b3e11e99779f698461214a6">In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, 949 F. Supp. 2d 1365 (J.P.M.L. 2013)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54931f26b3e11e99b03e53d6dd36aa2"><label.designator>12</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914075" w-serial-number="1978104662" w-seq-number="00114" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="603" ID="I6c171ff16b3e11e99779f698461214a6">In re Amoxicillin Patent and Antitrust Litigation, 449 F. Supp. 601, 603 (J.P.M.L. 1978)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54959006b3e11e99b03e53d6dd36aa2"><label.designator>13</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914075" w-serial-number="1969103260" w-seq-number="00115" w-ref-type="RP" w-pub-number="0000345" ID="I6c17bc316b3e11e99779f698461214a6">In re IBM, 302 F. Supp. 796 (J.P.M.L. 1969)</cite.query>. <eos/><bos/><cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs6.3.8" w-pub-number="185218" ID="If54959016b3e11e99b03e53d6dd36aa2">Section 6.3.8</cite.query> considers the role of the pendency of related government actions in selection of the transferee district.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54959026b3e11e99b03e53d6dd36aa2"><label.designator>14</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914075" w-serial-number="1975105292" w-seq-number="00116" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="569" ID="I6c1831616b3e11e99779f698461214a6">In re Stirling Homex Corp. Securities Litigation, 388 F. Supp. 567, 569–570 (J.P.M.L. 1975)</cite.query>. <eos/><bos/>The role of the pendency of reorganization proceedings is also discussed in <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs6:12" w-pub-number="185218" ID="If54980106b3e11e99b03e53d6dd36aa2">§ 6:12</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54980116b3e11e99b03e53d6dd36aa2"><label.designator>15</label.designator><footnote.body><para><bop/><bos/><paratext>In <cite.query w-src-number="0304914075" w-serial-number="2006585507" w-seq-number="00117" w-ref-type="RP" w-pub-number="0004637" ID="I6c1d61816b3e11e99779f698461214a6"><ital>In re Ace Ltd. Securities Litigation</ital>, 370 F. Supp. 2d 1353 (J.P.M.L. 2005)</cite.query>, the Panel had centralized another earlier docket against Ace Limited (MDL Docket No. 1663), in <cite.query w-src-number="0304914075" w-serial-number="2006265212" w-seq-number="00118" w-ref-type="RP" w-pub-number="0004637" ID="I6c1d61836b3e11e99779f698461214a6"><ital>In re Insurance Brokerage Antitrust Litigation</ital>, 360 F. Supp. 2d 1371 (J.P.M.L. 2005)</cite.query>, in the District of New Jersey, and selected the Eastern District of Pennsylvania for the later case. <eos/><bos/>The Panel also noted that the Eastern District of Pennsylvania was the only district suggested by any of the parties where an action was pending.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54980126b3e11e99b03e53d6dd36aa2"><label.designator>16</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914075" w-serial-number="2028783991" w-seq-number="00119" w-ref-type="RP" w-pub-number="0004637" ID="I6c1dfdc16b3e11e99779f698461214a6">In re Biomet M2a Magnum Hip Implant Products Liability Litigation, 896 F. Supp. 2d 1339 (J.P.M.L. 2012)</cite.query>. <eos/><bos/><ital>See also</ital> <cite.query w-src-number="0304914075" w-serial-number="2030714940" w-seq-number="00120" w-ref-type="RP" w-pub-number="0004637" ID="I6c1dfdc36b3e11e99779f698461214a6">In re Subway Footlong Sandwich Marketing and Sales Practices Litigation, 949 F. Supp. 2d 1369 (J.P.M.L. 2013)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54980136b3e11e99b03e53d6dd36aa2"><label.designator>17</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914075" w-serial-number="2007602296" w-seq-number="00121" w-ref-type="RP" w-pub-number="0004637" ID="I6c1e9a016b3e11e99779f698461214a6">In re American Investors Life Ins. Co. Annuity Marketing and Sales Practices Litigation, 398 F. Supp. 2d 1361 (J.P.M.L. 2005)</cite.query> (3 actions in transferee district had been pending a year longer; judge had greater familiarity).<eos/><bos/> The factor of relative advancement of cases on the docket is discussed in <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs6:16" w-pub-number="185218" ID="If54980146b3e11e99b03e53d6dd36aa2">§  6:16</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If54980156b3e11e99b03e53d6dd36aa2"><label.designator>18</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs6:13" w-pub-number="185218" ID="If549a7206b3e11e99b03e53d6dd36aa2">§ 6:13</cite.query>, above.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If549a7216b3e11e99b03e53d6dd36aa2"><label.designator>19</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914075" w-serial-number="2035414662" w-seq-number="00122" w-ref-type="RP" w-pub-number="0007903" ID="I6c1f5d516b3e11e99779f698461214a6">In re: Protegrity Corp. and Protegrity USA, Inc., Patent Litigation, 84 F. Supp. 3d 1380 (U.S.J.P.M.L. 2015)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If549a7226b3e11e99b03e53d6dd36aa2"><label.designator>20</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914075" w-serial-number="2035768097" w-seq-number="00123" w-ref-type="RP" w-pub-number="0007903" ID="I6c2020a16b3e11e99779f698461214a6">In re Industrial Print Technologies, LLC, 98 F. Supp. 3d 1378 (J.P.M.L. 2015)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2035414662" w-seq-number="00124" w-ref-type="RP" w-pub-number="0007903" ID="I6c2020a36b3e11e99779f698461214a6">In re: Protegrity Corp. and Protegrity USA, Inc., Patent Litigation, 84 F. Supp. 3d 1380 (U.S.J.P.M.L. 2015)</cite.query>; <cite.query w-src-number="0304914075" w-serial-number="2034977603" w-seq-number="00125" w-ref-type="RP" w-pub-number="0007903" ID="I6c2020a76b3e11e99779f698461214a6">In re: CTP Innovations, LLC, Patent Litigation, 65 F. Supp. 3d 1410 (U.S.J.P.M.L. 2014)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote></footnote.block><content.metadata.block><cmd.royalty><cmd.copyright><bop/><bos/>Westlaw. © 2019 Thomson Reuters.  <eos/><bos/>No Claim to Orig. U.S. Govt. <eos/><bos/>Works.<eos/><eop/></cmd.copyright></cmd.royalty><cmd.identifiers><cmd.cites><cmd.first.line.cite><bop/><bos/>MDLITMAN § 6:14<eos/><eop/></cmd.first.line.cite></cmd.cites></cmd.identifiers></content.metadata.block></doc></n-docbody>
